Hrt Financial LP Adaptimmune Therapeutics PLC Transaction History

Hrt Financial LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.43 - $0.79 $25,759 - $47,325	59,906 New	59,906 $47,000
Q1 2023 May 12, 2023	BUY	$1.06 - $2.16 $19,129 - $38,981	18,047 New	18,047 $19,000
Q2 2022 Aug 12, 2022	BUY	$1.33 - $2.28 $28,051 - $48,087	21,091 New	21,091 $35,000
Q3 2021 Nov 15, 2021	SELL	$3.44 - $6.37 $146,616 - $271,495	-42,621 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$3.86 - $5.78 $164,517 - $246,349	42,621 New	42,621 $181,000
Q1 2020 May 15, 2020	SELL	$1.2 - $4.52 $53,094 - $199,987	-44,245 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$0.72 - $1.43 $31,856 - $63,270	44,245 New	44,245 $53,000

145M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $96.4M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.